Crossmark

Content validation of an electronic remote toxicity management system in adult patients undergoing cancer treatment: a prospective longitudinal study on the QuestOnco application

Crossref DOI link: https://doi.org/10.1186/s12885-024-13312-4

Published Online: 2024-12-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Longo, Raffaele

Goetz, Christophe

Campitiello, Marco

Plastino, Francesca

Egea, Julie

Legros, Pierre-Olivier

Elnar, Arpiné Ardzivian

Meraihi, Salma

Luporsi, Elisabeth

Noirez, Véronique
License Information

Text and Data Mining valid from 2024-12-23

Version of Record valid from 2024-12-23
More Information

Article History

Received: 1 April 2024

Accepted: 9 December 2024

First Online: 23 December 2024

Declarations

:

: This study conformed to the tenets of the Helsinki Declaration and was approved by the Comité de Protection des Personnes-Ile de France III (number 2020-A03322-37). It was conducted under the reference methodology MR-001 from the Commission Nationale Informatique et Libertés (number 2226879v0), and was registered on ClinicalTrials.gov (No. NCT04915274). All patients consented in writing to participate in the study.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below